HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Depilatory and skin care sales up 3% to $27.5 mil. in second quarter, firm reports in 10Q filed with the Securities and Exchange Commission Aug. 8. Increase is led by 14% gain in Nair sales for the period (1"The Rose Sheet" Aug. 12, 2002, p. 5). Sales for smallest Armkel product category, oral care (Pearl Drops), soared 21% to $8.9 mil. for quarter. Results for the 50/50 Church and Dwight/Kelso & Co. partnership formed to purchase most Carter-Wallace consumer products are compared to C-W for previous year. Armkel total net sales advanced 1.8% to $115.9 mil. in Q2...

You may also be interested in...

Nair Retail Sales Rise 14% In Q2 On Line Extensions

Retail sales for Nair depilatories advanced 14% in the second quarter with the addition of new wax products, Church & Dwight reported Aug. 5

Virtual Adcom Vet Says In-Person Events May Be Better For Product Approval Recommendations

Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.

US FDA Eyes Ocular Risks With GlaxoSmithKline’s Myeloma Drug Belantamab

Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts